Lamotrigine | LTG | Anticonvulsant Agent | AmBeed-信号通路专用抑制剂

首页 / / / / Lamotrigine

拉莫三嗪 /Lamotrigine 99%+

货号：A551325 同义名： LTG;BW430C

Lamotrigine is a member of the sodium channel blocking class of antiepileptic drugs which can block L-, N-, and P-type calcium channels and has weak 5-HT3 receptor inhibition.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Lamotrigine 化学结构
CAS号：84057-84-1

Lamotrigine 3D分子结构
CAS号：84057-84-1

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Lamotrigine 纯度/质量文件产品仅供科研

货号：A551325 标准纯度： 99%+ 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024. Ambeed. [ A288696 ]; • JMC, 2024. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

Calcium Channel 亚型比较
钠通道亚型比较

产品名称	Ca2+ channel-like protein ↓ ↑	Calcium Channel ↓ ↑	Cav 2.2 ↓ ↑	其他靶点	纯度
CDC25B-IN-2	✔			Akt	99%+
Clevidipine		✔			99%+
Verapamil HCl		✔			99%
Amlodipine		✔			99%
Amlodipine maleate		✔			99%+
(+)-cis-Diltiazem HCl		✔			99%+
Zegocractin		++ Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM			99%+
Tanshinone IIA sulfonate sodium		✔			98%
Ulixacaltamide		++ hCaV3.1, IC50: 50 nM hCaV3.2, IC50: 110 nM			99%+
Dronedarone Hydrochloride		✔			99%+
Nitrendipine		+ Calcium channel, IC50: 95 nM			99%+
Efonidipine HCl monoethanolate		✔			98%
Cinnarizine		✔			98%
SEA0400		++ NCX, IC50: 33 nM		ROS,p38 MAPK,ERK	99%+
Fasudil HCl		✔		PKA,Rho	98%
ML-9		✔		Akt,MLCK	99%+
Flunarizine 2HCl		+ Calcium channel, Ki: 68 nM			95%
Lomerizine 2HCl		✔			98%
Efonidipine		✔			98%
Levamlodipine		✔			97%
Nisoldipine		++ L-type Cav1.2, IC50: 10 nM			99%+
Isradipine		✔			99%+
Lacidipine		✔			99%+
Lercanidipine		✔			99%+
Loureirin B		✔		Potassium Channel	99%+
Tetracaine HCl		✔			98%
Manidipine		+++ Calcium channel, IC50: 2.6 nM			99%+
Manidipine Dihydrochlorid		+++ Calcium channel, IC50: 2.6 nM			98%
Nicardipine		✔			99%+
Wilforgine		✔			98+%
Econazole		✔			99%+
Ginsenoside Rd		✔		NF-κB	98%
Fendiline HCl		✔			98+%
Mesaconitine		✔			98%
Tetrandrine		✔			95%
Nifedipine		✔			95%
Nilvadipine		++++ Calcium channel, IC50: 0.03 nM			98%
Barnidipine		++++ [³H]nitrendipine, Ki: 0.21 nM			95+%
Azelnidipine		✔			97%
Levetiracetam		✔			98%
Nimodipine		✔			99%+
Benidipine HCl		✔			99%+
Pinaverium bromide		✔			98%
Pranidipine		✔			98%
NP118809		+ L-type calcium channel, IC50: 12.2 μM N-type Ca2+ channel, IC50: 0.11 μM			99%+
Amlodipine Besylate		+++ Calcium channel, IC50: 1.9 nM			99%+
Cilnidipine		✔			99%+
Cinepazide Maleate		✔			99%+
Terfenadine		✔			99%+
YM-58483		✔			99%+
Ranolazine		✔			99%+
Praeruptorin A		✔		Akt,p38 MAPK	98%
Ranolazine 2HCl		✔			98%
Felodipine		++++ L-type calcium channel, IC50: 0.15 nM			99%+
PD173212		+++ N-type Ca2+ channel, IC50: 36 nM			98%
Levamlodipine besylate		✔			97%
Carboxyamidotriazole Orotate		✔			99%+
IGS-1.76		✔			99%+
WH-4-023		++++ Cav 2.2, IC50: 0.001 μM	++++ Cav 2.2, IC50: 0.001 μM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Sodium Channel ↓ ↑	纯度
Tolperisone HCl	✔	99%
Lamotrigine	✔	99%+
Vinpocetine	✔	99%+
Zonisamide	✔	99%+
Dronedarone Hydrochloride	✔	99%+
Procainamide hydrochloride	✔	99%
Bupivacaine HCl	✔	99+%
Benzocaine	✔	99%+
Carbamazepine	++ Sodium channel, IC50: 131 μM	99%+
Ibutilide fumarate	✔	99%+
Dibucaine HCl	✔	99+%
Mexiletine HCl	✔	99%
Phenytoin	✔	99+%
Camostat Mesylate	+++ epithelial sodium channel (ENaC), IC50: 50 nM	99%+
Levobupivacaine	✔	97+%
Oxcarbazepine	+ sodium channel, IC50: 160 μM	98%
Ambroxol		98+%
Primidone	✔	99%
Propafenone	✔	99%
A-803467	++++ Na(V1.8) channel, IC50: 8 nM	99%+
Rufinamide	✔	99%
Phenytoin sodium	✔	99%+
Proparacaine Hydrochloride	+ Voltage-gated sodium channel, ED50: 3.4 mM	99%+
Riluzole	✔	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Lamotrigine 生物活性

靶点

5-HT

5-HT (human platelets), IC50:240 μM

5-HT (rat brain synaptosomes), IC50:474 μM
Sodium Channel

描述

Lamotrigine belongs to the second generation of antiepileptic drugs (AEDs)^[3]. Co-application of lamotrigine (1 ~ 300 µM) resulted in a concentration-dependent reduction in peak amplitude of currents induced by 3 µM of 5-HT for an IC50 value of 28.2 ± 3.6 µM with a Hill coefficient of 1.2 ± 0.1^[4]. Moreover, intrathecally administered lamotrigine could prevent the activation of the glutamate receptors involved in pain transmission and central sensitization, such as AMPA, NMDA, and metabotropic receptors^[5]. Studies showed lamotrigine could ameliorate executive dysfunction and brain inflammatory response in the mouse model of AD^[6].

Lamotrigine 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00206778	Mixed Mania Bipolar Disorder	Phase 2	Completed	-	United States, New York ... 展开 >> Beth Israel Medical Center New York, New York, United States, 10003 收起 <<
NCT00104416	Epilepsy, Tonic-Clonic	Phase 3	Completed	-	-
NCT02283801	Epilepsy	Phase 1	Completed	-	-

Lamotrigine 参考文献

[1]Goa KL, Ross SR, et al. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1993 Jul;46(1):152-76.

[2]Leach MJ, Marden CM, et al. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 1986 Sep-Oct;27(5):490-7.

[3] Lovrić M, Čajić I, Petelin Gadže Ž, Klarica Domjanović I, Božina N. Effect of antiepileptic drug comedication on lamotrigine concentrations. Croat Med J. 2018 Feb 28;59(1):13-19.

[4]Kim KJ, Jeun SH, Sung KW. Lamotrigine, an antiepileptic drug, inhibits 5-HT3 receptor currents in NCB-20 neuroblastoma cells. Korean J Physiol Pharmacol. 2017 Mar;21(2):169-177.

[5]Jun IG, Kim SH, Yoon YI, Park JY. Intrathecal lamotrigine attenuates antinociceptive morphine tolerance and suppresses spinal glial cell activation in morphine-tolerant rats. J Korean Med Sci. 2013 Feb;28(2):300-7.

[6]Wang K, Fernandez-Escobar A, Han S, Zhu P, Wang JH, Sun Y. Lamotrigine Reduces Inflammatory Response and Ameliorates Executive Function Deterioration in an Alzheimer's-Like Mouse Model. Biomed Res Int. 2016;2016:7810196

Lamotrigine 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.90mL

0.78mL

0.39mL

19.52mL

3.90mL

1.95mL

39.05mL

7.81mL

3.90mL

Lamotrigine 技术信息

CAS号	84057-84-1
分子式	C₉H₇Cl₂N₅
分子量	256.091

别名	LTG;BW430C;Lamotrigine, Lamictal, BW-430C, Crisomet, Lamictin, Lamitor
运输	蓝冰

存储条件

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 25 mg/mL(97.62 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00206778	Mixed Mania Bipolar Disorder	Phase 2	Completed	-	United States, New York ... 展开 >> Beth Israel Medical Center New York, New York, United States, 10003 收起 <<
NCT00104416	Epilepsy, Tonic-Clonic	Phase 3	Completed	-	-
NCT02283801	Epilepsy	Phase 1	Completed	-	-
NCT00188643	Bipolar Disorder	Phase 4	Completed	-	Canada, Ontario ... 展开 >> Toronto Western Hospital Toronto, Ontario, Canada, M5T2S8 收起 <<
NCT00104416	-		Completed	-	-
NCT00723450	Bipolar Disorder	Phase 3	Completed	-	-
NCT00627575	Epilepsy	Phase 1	Completed	-	United States, New York ... 展开 >> GSK Investigational Site Buffalo, New York, United States, 14202 收起 <<
NCT00264680	-		Completed	-	-
NCT00723450	-		Completed	-	-
NCT00321516	Bipolar Disorder	Phase 1	Completed	-	United States, Pennsylvania ... 展开 >> Local Institution Philadelphia, Pennsylvania, United States United States, Texas Local Institution Austin, Texas, United States Local Institution Bellaire, Texas, United States Local Institution Desota, Texas, United States 收起 <<
NCT00257855	Secondary Progressive Multiple... 展开 >> Sclerosis 收起 <<	Phase 2	Completed	-	United Kingdom ... 展开 >> National Hospital for Neurology and Neurosurgery London, United Kingdom, WC1 3BG 收起 <<
NCT00939458	Healthy	Phase 1	Completed	-	India ... 展开 >> Lotus Labs Pvt. Ltd. Bangalore, Karnataka, India 收起 <<
NCT01142310	Memory Impairment	Phase 4	Completed	-	United States, Texas ... 展开 >> Parkland Health and Hospital System (Asthma, Allergy, & Arthritis Clinics) Dallas, Texas, United States, 75235 收起 <<
NCT01055327	-		Completed	-	-
NCT00226135	Bipolar Disorder	Phase 3	Completed	-	Denmark ... 展开 >> Aarhus University Psychiatric Hospital Risskov, Denmark, 8240 收起 <<
NCT01428518	-		Completed	-	-
NCT00203229	Trigeminal Neuralgia	Not Applicable	Completed	-	United States, Pennsylvania ... 展开 >> Jefferson Headache Center Philadelphia, Pennsylvania, United States, 19107 收起 <<
NCT00203229	-		Completed	-	-
NCT00153244	Bronchial Asthma	Phase 4	Completed	-	-
NCT00264615	Epilepsy	Phase 3	Completed	-	United States, Alabama ... 展开 >> GSK Investigational Site Anniston, Alabama, United States, 36207 United States, Arizona GSK Investigational Site Sun City, Arizona, United States, 85351 United States, Kentucky GSK Investigational Site Lexington, Kentucky, United States, 40503 GSK Investigational Site Lexington, Kentucky, United States, 40536-0284 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02215 United States, Nevada GSK Investigational Site Reno, Nevada, United States, 89521 United States, New York GSK Investigational Site New York, New York, United States, 10016 United States, Ohio GSK Investigational Site Toledo, Ohio, United States, 43614-5809 United States, Pennsylvania GSK Investigational Site Philadelphia, Pennsylvania, United States, 19140 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site Dallas, Texas, United States, 75230 United States, Virginia GSK Investigational Site Richmond, Virginia, United States, 23219 收起 <<
NCT00650208	Healthy	Phase 1	Completed	-	United States, West Virginia ... 展开 >> Kendle International Inc. Morgantown, West Virginia, United States, 26505 收起 <<
NCT00647751	Healthy	Phase 1	Completed	-	United States, West Virginia ... 展开 >> Kendle International Inc. Morgantown, West Virginia, United States, 26505 收起 <<
NCT00068445	Neurotoxicity ... 展开 >> Pain Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 3	Completed	-	-
NCT01015586	Alcohol Dependence ... 展开 >> Bipolar Disorder Depression Mania Psychosis 收起 <<	Phase 4	Unknown	May 2014	United States, South Carolina ... 展开 >> Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29425 Contact: Bryan K Tolliver, M.D., Ph.D. 843-792-5215 tollive@musc.edu 收起 <<
NCT01142310	-		Completed	-	-
NCT00360126	Bipolar Disorder	Phase 4	Completed	-	Australia, New South Wales ... 展开 >> GSK Investigational Site Greenwich, New South Wales, Australia, 2065 Australia, Queensland GSK Investigational Site Everton Park, Queensland, Australia, 4053 GSK Investigational Site New Farm, Queensland, Australia, 4005 收起 <<
NCT00068445	-		Completed	-	-
NCT00939614	Healthy	Phase 1	Completed	-	India ... 展开 >> Lotus Labs Pvt. Ltd. Bangalore, Karnataka, India, 560 052 收起 <<
NCT00360126	-		Completed	-	-
NCT00652171	Depression	Phase 3	Completed	-	-
NCT00579982	Mood Disorders	Phase 3	Completed	-	United States, California ... 展开 >> GSK Investigational Site San Diego, California, United States, 92108 GSK Investigational Site Santa Ana, California, United States, 92705 United States, Florida GSK Investigational Site Jacksonville, Florida, United States, 32257 GSK Investigational Site Orange City, Florida, United States, 32763 GSK Investigational Site Winter Park, Florida, United States, 32792 United States, Georgia GSK Investigational Site Marietta, Georgia, United States, 30060 United States, Illinois GSK Investigational Site Fairview Heights, Illinois, United States, 62208 United States, Minnesota GSK Investigational Site Minneapolis, Minnesota, United States, 55454 United States, Missouri GSK Investigational Site St. Charles, Missouri, United States, 63301 United States, New York GSK Investigational Site Olean, New York, United States, 14760 United States, North Carolina GSK Investigational Site Raleigh, North Carolina, United States, 27609 United States, Ohio GSK Investigational Site Cincinnati, Ohio, United States, 45243 GSK Investigational Site Cleveland, Ohio, United States, 44106 United States, Texas GSK Investigational Site Arlington, Texas, United States, 76012 GSK Investigational Site Houston, Texas, United States, 77014 GSK Investigational Site Houston, Texas, United States, 77042 United States, Virginia GSK Investigational Site Norfolk, Virginia, United States, 23505 United States, West Virginia GSK Investigational Site Charleston, West Virginia, United States, 25301 收起 <<
NCT00579982	-		Completed	-	-
NCT00280293	Bipolar Disorder ... 展开 >> Cocaine Dependence 收起 <<	Phase 4	Completed	-	United States, Texas ... 展开 >> UT Southwestern Medical Center at Dallas Dallas, Texas, United States, 75390-8849 收起 <<
NCT00224510	Bipolar Disorder ... 展开 >> Bipolar Depression 收起 <<	Phase 3	Completed	-	Netherlands ... 展开 >> GSK Investigational Site Alkmaar, Netherlands, 1815 JD GSK Investigational Site Almelo, Netherlands, 7609 PP GSK Investigational Site Amersfoort, Netherlands, 3818 EW GSK Investigational Site Amsterdam, Netherlands, 1061 AE GSK Investigational Site Amsterdam, Netherlands, 1075 GB GSK Investigational Site Bennebroek, Netherlands, 2121 AD GSK Investigational Site Blaricum, Netherlands, 1261 AN GSK Investigational Site Delft, Netherlands, 2625 AD GSK Investigational Site Den Haag, Netherlands, 2553 RJ GSK Investigational Site Dordrecht, Netherlands, 3317 NM GSK Investigational Site Eindhoven, Netherlands, 5623 EJ GSK Investigational Site Enschede, Netherlands, 7511JX GSK Investigational Site Gouda, Netherlands, 2803 RT GSK Investigational Site Groningen, Netherlands, 9713 GZ GSK Investigational Site Hoorn, Netherlands, 1624 NP GSK Investigational Site Leiden, Netherlands, 2333 ZB GSK Investigational Site Nijmegen, Netherlands, 6532 SZ GSK Investigational Site Raalte, Netherlands, 8102 RR GSK Investigational Site Retranchement, Netherlands, 4525 LG GSK Investigational Site Rosmalen, Netherlands, 5248 NT GSK Investigational Site Tilburg, Netherlands, 5022 GC GSK Investigational Site Utrecht, Netherlands, 3512 PG GSK Investigational Site Vlissingen, Netherlands, 4382 EE GSK Investigational Site Weert, Netherlands, 6001 BE GSK Investigational Site Zwolle, Netherlands, 8025 AB Spain GSK Investigational Site Alava, Spain, 01004 GSK Investigational Site Barcelona, Spain, 08025 GSK Investigational Site Barcelona, Spain, 08035 GSK Investigational Site Barcelona, Spain, 08036 GSK Investigational Site Madrid, Spain, 28035 GSK Investigational Site Valencia, Spain, 46009 收起 <<
NCT00277212	-		Completed	-	-
NCT00280293	-		Completed	-	-
NCT01431976	Epilepsy	Phase 3	Completed	-	Japan ... 展开 >> GSK Investigational Site Aichi, Japan, 453-8511 GSK Investigational Site Ehime, Japan, 790-8524 GSK Investigational Site Ehime, Japan, 791-0295 GSK Investigational Site Fukuoka, Japan, 807-8555 GSK Investigational Site Fukuoka, Japan, 814-0180 GSK Investigational Site Hiroshima, Japan, 730-8518 GSK Investigational Site Hokkaido, Japan, 006-0041 GSK Investigational Site Hokkaido, Japan, 060-8648 GSK Investigational Site Kanagawa, Japan, 232-8555 GSK Investigational Site Niigata, Japan, 950-2085 GSK Investigational Site Okayama, Japan, 700-8558 GSK Investigational Site Shizuoka, Japan, 430-8558 GSK Investigational Site Tokyo, Japan, 113-8603 Korea, Republic of GSK Investigational Site Seoul, Korea, Republic of, 120-752 收起 <<
NCT01431976	-		Completed	-	-
NCT01607086	Mental Disorders	Phase 1	Completed	-	United Kingdom ... 展开 >> GSK Investigational Site Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ 收起 <<
NCT01431963	Epilepsy	Phase 3	Completed	-	Japan ... 展开 >> GSK Investigational Site Fukuoka, Japan, 807-8555 GSK Investigational Site Ibaraki, Japan, 317-0077 GSK Investigational Site Kagoshima, Japan, 892-0844 GSK Investigational Site Kyoto, Japan, 611-0042 GSK Investigational Site Miyagi, Japan, 980-8574 GSK Investigational Site Nara, Japan, 634-8522 GSK Investigational Site Niigata, Japan, 950-1197 GSK Investigational Site Niigata, Japan, 950-2085 GSK Investigational Site Okayama, Japan, 703-8265 GSK Investigational Site Osaka, Japan, 560-8565 GSK Investigational Site Shizuoka, Japan, 430-8558 Korea, Republic of GSK Investigational Site Seoul, Korea, Republic of, 110-744 GSK Investigational Site Seoul, Korea, Republic of, 135-710 收起 <<
NCT00242606	Epilepsy	Phase 3	Completed	-	Germany ... 展开 >> Philipps University Marburg Medical Center, Department of Neurology Marburg, Germany, 35033 收起 <<
NCT00410371	Mental Disorders	Phase 1	Completed	-	United States, Nebraska ... 展开 >> GSK Investigational Site Lincoln, Nebraska, United States, 68502 收起 <<
NCT01431963	-		Completed	-	-
NCT00277212	Bipolar Disorder	Phase 4	Completed	-	-
NCT00513019	-		Completed	-	-
NCT00513019	Neurotic Excoriation ... 展开 >> Pathologic Skin Picking Psychogenic Excoriation Dermatillomania 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> Ambulatory Research Center Minneapolis, Minnesota, United States, 55454 收起 <<
NCT00947375	Schizophrenia	Phase 4	Terminated(All of the mentione... 展开 >>d aim and objectives were achieved before the February 2007) 收起 <<	-	Azerbaijan ... 展开 >> Central Mental Clinic for Outpatients of Baku City Baku, Azerbaijan, AZ0010 收起 <<
NCT00266149	Epilepsy	Phase 3	Terminated	-	Denmark ... 展开 >> Department of Neurology, Aarhus University Hospital Aarhus, Denmark, 8000 收起 <<
NCT01863602	-		Completed	-	-
NCT00277641	Binge Eating Disorder ... 展开 >> Obesity 收起 <<	Phase 3	Completed	-	United States, Ohio ... 展开 >> Lindner Center of HOPE Mason, Ohio, United States, 45040 收起 <<
NCT00901407	Unipolar Depression	Not Applicable	Completed	-	United States, Louisiana ... 展开 >> LSUHSC- New Orleans New Orleans, Louisiana, United States, 70115 收起 <<
NCT00634062	Borderline Personality Disorde... 展开 >>r 收起 <<	Phase 4	Completed	-	United States, Massachusetts ... 展开 >> McLean Hospital Belmont, Massachusetts, United States, 02478 收起 <<
NCT00917839	Relapsing-Remitting Multiple S... 展开 >>clerosis 收起 <<	Phase 2	Unknown	December 2011	Switzerland ... 展开 >> Cantonal Hospital St. Gallen Recruiting St. Gallen, Switzerland, 9007 Contact: Norman Putzki, MD +4171494 ext 1663 norman.putzki@kssg.ch Principal Investigator: Norman Putzki, MD Sub-Investigator: Ozgur Yaldizli, MD 收起 <<
NCT00838136	-		Completed	-	-
NCT00838279	-		Completed	-	-
NCT00835263	-		Completed	-	-
NCT00834561	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 收起 <<
NCT00838279	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Sainte-Foy, Quebec, Canada, GIV2K8 收起 <<
NCT00834561	-		Completed	-	-
NCT00835263	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 收起 <<
NCT00460226	-		Completed	-	-
NCT01618799	Fasting State	Phase 1	Completed	-	India ... 展开 >> Cliantha Research Limited Ahmedabad, Gujarat, India 收起 <<
NCT00838136	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Sainte-Foy, Quebec, Canada, GIV2K8 收起 <<
NCT00550407	-		Completed	-	-
NCT00412191	Epilepsy	Phase 1	Completed	-	Germany ... 展开 >> GSK Investigational Site Berlin, Germany, 14050 收起 <<
NCT01618825	Fed	Phase 1	Completed	-	India ... 展开 >> Cliantha Research Limited Ahmedabad, Gujarat, India 收起 <<
NCT00550407	Bipolar Disorder	Phase 3	Completed	-	-
NCT00355082	Epilepsy, Partial	Phase 3	Completed	-	-
NCT00516139	-		Completed	-	-
NCT00355082	-		Completed	-	-
NCT02100644	-		Completed	-	-
NCT00566020	Bipolar Disorder	Phase 3	Completed	-	-
NCT01064297	-		Completed	-	-
NCT00516139	Epilepsy	Phase 3	Completed	-	-
NCT01064297	-		Completed	-	-
NCT02100644	Epilepsy	Phase 4	Completed	-	Japan ... 展开 >> GSK Investigational Site Hyogo, Japan, 664-8540 GSK Investigational Site Kagoshima, Japan, 892-0844 GSK Investigational Site Kyoto, Japan, 606-8507 GSK Investigational Site Osaka, Japan, 560-8565 GSK Investigational Site Saitama, Japan, 351-8551 GSK Investigational Site Shizuoka, Japan, 430-8558 GSK Investigational Site Tokyo, Japan, 185-0012 收起 <<
NCT00913107	Trigeminal Neuralgia	Phase 2 Phase 3	Completed	-	Malaysia ... 展开 >> Dept. of OMOP, Faculty of Dentistry, University Malaya. Kuala Lumpur, Malaysia, 50603 Dept. of Oral Medicine and Oral Pathology, Faculty of Dentistry, University Malaya. Kuala Lumpur, Malaysia, 50603 收起 <<
NCT01602510	Bipolar Disorder	Phase 3	Completed	-	China, Guangdong ... 展开 >> GSK Investigational Site Guangzhou, Guangdong, China, 510180 GSK Investigational Site Guangzhou, Guangdong, China, 510370 GSK Investigational Site Guangzhou, Guangdong, China, 510630 China, Hebei GSK Investigational Site Baoding, Hebei, China, 071000 GSK Investigational Site Shijiazhuang, Hebei, China, 050000 China, Heilongjiang GSK Investigational Site Harbin, Heilongjiang, China, 150070 China, Henan GSK Investigational Site Changsha, Henan, China, 410011 GSK Investigational Site Xinxiang, Henan, China China, Hubei GSK Investigational Site Wuhan, Hubei, China, 430022 China, Hunan GSK Investigational Site Changsha, Hunan, China China, Jiangsu GSK Investigational Site Nanjing, Jiangsu, China, 210029 China, Shaanxi GSK Investigational Site Xi'an, Shaanxi, China, 710032 China, Shanxi GSK Investigational Site Taiyuan, Shanxi, China China, Sichuan GSK Investigational Site Chengdu, Sichuan, China, 610041 China, Yunnan GSK Investigational Site Kunming, Yunnan, China, 650032 China, Zhejiang GSK Investigational Site Hangzhou, Zhejiang, China, 310003 GSK Investigational Site Hangzhou, Zhejiang, China, 310009 China GSK Investigational Site Beijing, China, 100083 GSK Investigational Site Beijing, China, 100088 GSK Investigational Site Beijing, China, 100096 GSK Investigational Site Shanghai, China, 200030 收起 <<
NCT01376180	-		Completed	-	-
NCT02404168	Epilepsy	Phase 4	Unknown	December 2015	United States, Maryland ... 展开 >> University of Maryland Baltimore, Maryland, United States, 21201 收起 <<
NCT00618241	HIV Infection	Phase 1	Completed	-	Netherlands ... 展开 >> Radboud University Medical Center Nijmegen, Gelderland, Netherlands 收起 <<
NCT00566020	-		Completed	-	-
NCT01888250	Healthy	Phase 1	Completed	-	India ... 展开 >> Bioserve Clinical Research Private Limited Balanagar, Hyderabad, India, 500 037 收起 <<
NCT01888731	Healthy	Phase 1	Completed	-	India ... 展开 >> Bioserve Clinical Research Private Limited Balanagar, Hyderabad, India, 500 037 收起 <<
NCT00605371	Epilepsy	Phase 1	Completed	-	United States, Washington ... 展开 >> GSK Investigational Site Tacoma, Washington, United States, 98418 收起 <<
NCT00181844	Bipolar Disorder ... 展开 >> Mania 收起 <<	Phase 4	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cambridge, Massachusetts, United States, 02138 收起 <<
NCT01888263	Healthy	Phase 1	Completed	-	India ... 展开 >> Bioserve Clinical Research Private Limited Balanagar, Hyderabad, India, 500 037 收起 <<
NCT00181844	-		Completed	-	-
NCT00144872	Seizure, Absence	Phase 1	Completed	-	United States, California ... 展开 >> GSK Investigational Site San Jose, California, United States, 95128 United States, Florida GSK Investigational Site Loxahatchee Groves, Florida, United States, 33470 GSK Investigational Site Melbourne, Florida, United States, 32901 GSK Investigational Site Panama City, Florida, United States, 32405 GSK Investigational Site Tallahassee, Florida, United States, 32308 GSK Investigational Site Tampa, Florida, United States, 33607-6350 United States, Georgia GSK Investigational Site Atlanta, Georgia, United States, 30342 United States, Kentucky GSK Investigational Site Louisville, Kentucky, United States, 40202 United States, Missouri GSK Investigational Site Springfield, Missouri, United States, 65804 United States, New Jersey GSK Investigational Site Newark, New Jersey, United States, 07103 United States, New York GSK Investigational Site Buffalo, New York, United States, 14222 GSK Investigational Site Rochester, New York, United States, 14642 United States, North Carolina GSK Investigational Site Chapel Hill, North Carolina, United States, 27599-7600 GSK Investigational Site Greenville, North Carolina, United States, 27834 GSK Investigational Site Raleigh, North Carolina, United States, 27607 United States, Oregon GSK Investigational Site Portland, Oregon, United States, 97239 United States, Tennessee GSK Investigational Site Germantown, Tennessee, United States, 38138 GSK Investigational Site Nashville, Tennessee, United States, 37212 United States, Texas GSK Investigational Site Fort Worth, Texas, United States, 76104 United States, Washington GSK Investigational Site Seattle, Washington, United States, 98105 United States, Wisconsin GSK Investigational Site Madison, Wisconsin, United States, 53792 GSK Investigational Site Milwaukee, Wisconsin, United States, 53215 GSK Investigational Site Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT01888757	Healthy	Phase 1	Completed	-	India ... 展开 >> Bioserve Clinical Research Private Limited Balanagar, Hyderabad, India, 500 037 收起 <<
NCT01357902	Epilepsy	Phase 1	Completed	-	Hong Kong ... 展开 >> GSK Investigational Site Shatin, New Territories, Hong Kong 收起 <<
NCT01602510	-		Completed	-	-
NCT00720473	-		Completed	-	-
NCT00720473	Bipolar Depression	Not Applicable	Completed	-	United States, Massachusetts ... 展开 >> McLean Hospital Belmont, Massachusetts, United States, 02478 收起 <<
NCT01657864	-		Completed	-	-
NCT00176228	-		Completed	-	-
NCT00243152	Facial Neuropathy	Not Applicable	Completed	-	United States, Massachusetts ... 展开 >> McLean Hospital Neuroimaging Center, 115 Mill Street Belmont, Massachusetts, United States, 02478 收起 <<
NCT03419949	-		-	-	Egypt ... 展开 >> Salma Komy Assiut, Egypt 收起 <<
NCT00176228	Bipolar Disorder	Phase 2	Completed	-	United States, Illinois ... 展开 >> NPI, University of Illinois at Chicago Chicago, Illinois, United States, 60612 收起 <<
NCT00896987	Epilepsy	Phase 4	Completed	-	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Korea, Republic of 收起 <<
NCT01042496	Bipolar Depression	Phase 3	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic in Rochester Rochester, Minnesota, United States, 55905 收起 <<
NCT01042496	-		Completed	-	-
NCT00621842	Bipolar Disorder ... 展开 >> Depression, Bipolar 收起 <<	Phase 3	Completed	-	United States, New York ... 展开 >> Weill Medical College of Cornell University White Plains, New York, United States, 10605 United States, Ohio University Hospitals Case Medical Center/ Case Western Reserve University Cleveland, Ohio, United States, 44106 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic Pittsburgh, Pennsylvania, United States, 15213 United States, Texas Baylor College of Medicine/Michael E. DeBakey VAMC Houston, Texas, United States, 77030 收起 <<
NCT01864551	Bipolar Disorder	Phase 4	Completed	-	Taiwan ... 展开 >> Tri-Service General Hospital Taipei, Taiwan, 114 收起 <<
NCT00243152	-		Completed	-	-
NCT00449774	Mental Disorders	Phase 1	Completed	-	United States, Texas ... 展开 >> GSK Investigational Site Dallas, Texas, United States, 75247 收起 <<
NCT02556060	Addiction	Phase 2 Phase 3	Completed	-	Taiwan ... 展开 >> Taipei City Hospital and Psychiatric Center Taipei, Taiwan, 110 收起 <<
NCT00621842	-		Completed	-	-
NCT02389712	Bipolar Disorder	Phase 4	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT01513720	Healthy	Phase 1	Completed	-	United States, North Carolina ... 展开 >> AAI Clinic Quadrangle drive, North Carolina, United States, 27514 收起 <<
NCT00789113	-		Completed	-	-
NCT01513681	Healthy	Phase 1	Completed	-	United States, North Carolina ... 展开 >> AAI Clinic Quadrangle drive, North Carolina, United States, 27514 收起 <<
NCT00789113	Epilepsy Seiz... 展开 >>ures Bipolar Disorder Bipolar Depression 收起 <<	Phase 1 Phase 2	Completed	-	United States, Minnesota ... 展开 >> University of Minnesota Minneapolis, Minnesota, United States, 55404 收起 <<
NCT02256124	Neurofibromatosis Type 1	Phase 2 Phase 3	Recruiting	July 2019	Belgium ... 展开 >> University Hospital Leuven Recruiting Leuven, Belgium, B-3000 Contact: Eric Legius, MD, PhD +3216345903 eric.legius@uzleuven.be Contact: Ellen Plasschaert, MSc +3216345903 ellen.plasschaert@uzleuven.be Sub-Investigator: Ellen Plasschaert, MSc Principal Investigator: Eric Legius, MD, PhD Netherlands Erasmus Medical Center Recruiting Rotterdam, South Holland, Netherlands, 3015CN Principal Investigator: Marie-Claire Y de Wit, MD, PhD Sub-Investigator: Myrthe Ottenhoff, MD, MSc Spain Hospital Sant Joan de Deu Recruiting Barcelona, Spain Contact: Hector Salvador Hernandez, Dr. 收起 <<
NCT01131949	Healthy	Phase 1	Completed	-	United States, North Carolina ... 展开 >> AAI Clinic Chapel Hill, North Carolina, United States, 27514 收起 <<
NCT01939561	Dystrophia Myotonica Type 1 ... 展开 >> Myotonia Congenita Paramyotonia Congenita Hyperkalemic Periodic Paralysis Potassium-Aggravated Myotonia 收起 <<	Phase 3	Completed	-	Denmark ... 展开 >> Copenhagen Neuromuscular Center, department of Neurology, Rigshospitalet Copenhagen, Denmark, DK-2100 收起 <<
NCT02158585	Meniere's Disease ... 展开 >> Ménière's Vertigo Vertigo, Intermittent Vertigo, Aural 收起 <<	Phase 3	Completed	-	United States, New York ... 展开 >> Dent Neurologic Institute Amherst, New York, United States, 14226 收起 <<
NCT01879423	Epilepsy	Phase 1	Completed	-	China ... 展开 >> GSK Investigational Site Shanghai, China, 200030 收起 <<
NCT02989727	Depression Bi... 展开 >>polar Disorder Bipolar Depression Melancholia Lamotrigine 收起 <<	Phase 4	Unknown	November 2017	Canada, Saskatchewan ... 展开 >> Department of Psychiatry, Royal University Hospital Saskatoon, Saskatchewan, Canada, S7N0W8 收起 <<
NCT01131975	Healthy	Phase 1	Completed	-	United States, North Carolina ... 展开 >> AAI Clinic Chapel Hill, North Carolina, United States, 27514 收起 <<
NCT01995825	Epilepsy	Phase 4	Completed	-	United States, Maryland ... 展开 >> University of Maryland Baltimore, Maryland, United States, 21201 收起 <<
NCT03497143	-		Recruiting	October 2026	Norway ... 展开 >> St. Olavs University Hospital Recruiting Trondheim, Norway Contact: Magnus Strømmen, MSc 收起 <<
NCT02303106	Healthy	Phase 4	Completed	-	Denmark ... 展开 >> University of Southern Denmark Odense, Denmark, 5210 收起 <<
NCT00475137	Bipolar II Disorder, Most Rece... 展开 >>nt Episode Major Depressive 收起 <<	Phase 2	Completed	-	Canada, British Columbia ... 展开 >> University of British Columbia Mood Disorders Centre Vancouver, British Columbia, Canada 收起 <<
NCT02513654	Bipolar Disorder	Phase 1	Completed	-	China ... 展开 >> GSK Investigational Site Shanghai, China, 200030 收起 <<
NCT03220256	Lamotrigine Allergy	Phase 2	Recruiting	August 1, 2018	Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Sang Kun Lee, MD, PhD sangkun2923@gmail.com Principal Investigator: Sang Kun Lee, MD, PhD 收起 <<
NCT03774641	-		Recruiting	December 31, 2020	United States, Maryland ... 展开 >> 550 N Broadway Recruiting Baltimore, Maryland, United States, 21205 Contact: Courtney N Erdly Principal Investigator: Jennifer L Payne, MD 收起 <<
NCT01996293	-		Unknown	September 2017	United States, Illinois ... 展开 >> Northwestern Memorial Hospital Recruiting Chicago, Illinois, United States, 60611 Contact: Crystal T Clark, MD, MSc 312-695-8648 crystal.clark@northwestern.edu Principal Investigator: Crystal T Clark, MD, MSc 收起 <<
NCT02064465	Epilepsy	Phase 1	Completed	-	China ... 展开 >> GSK Investigational Site Shanghai, China, 200030 收起 <<
NCT02821338	Healthy	Phase 1	Completed	-	United States, Kansas ... 展开 >> Vince and Associates Clinical Research, Inc Overland Park, Kansas, United States, 66212 收起 <<
NCT02707965	Epilepsy	Phase 4	Completed	-	United States, Maryland ... 展开 >> University of Maryland, Baltimore Baltimore, Maryland, United States, 21201 收起 <<
NCT00001478	-		Completed	-	United States, Maryland ... 展开 >> National Institute of Mental Health (NIMH) Bethesda, Maryland, United States, 20892 收起 <<
NCT00012558	Bipolar Disorder	Not Applicable	Completed	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305-5723 United States, Colorado University of Colorado, Colorado Psychiatric Health Clinical Investigation Center Denver, Colorado, United States, 80220 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 University of Massachusetts Medical Center Worcester, Massachusetts, United States, 01655 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 United States, Oklahoma University of Oklahoma Health Sciences Center Tulsa, Oklahoma, United States, 74135 United States, Oregon Portland Veteran's Administration Medical Center Portland, Oregon, United States, 97201 United States, Pennsylvania University of Pennsylvania Medical Center Philadelphia, Pennsylvania, United States, 19104-2649 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78229-3900 收起 <<
NCT00177567	Bipolar Disorder	Phase 4	Completed	-	United States, Pennsylvania ... 展开 >> University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15213 University of Pittsubrgh Medical Center Pittsburgh, Pennsylvania, United States, 15213 收起 <<
NCT02374567	Dementia Depr... 展开 >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders 收起 <<	Phase 3	Terminated	-	Germany ... 展开 >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany 收起 <<
NCT00552526	Epilepsy Ment... 展开 >>al Retardation 收起 <<	Phase 4	Unknown	December 2013	Norway ... 展开 >> SSE, Nevrological dep. , Rikshospitalet University hospital Oslo, Norway 收起 <<
NCT00404248	Brain and Central Nervous Syst... 展开 >>em Tumors 收起 <<	Phase 1 Phase 2	Completed	-	United States, Alabama ... 展开 >> UAB Comprehensive Cancer Center Birmingham, Alabama, United States, 35294-3410 United States, Florida H. Lee Moffitt Cancer Center and Research Institute at University of South Florida Tampa, Florida, United States, 33612-9497 United States, Georgia Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Michigan Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, North Carolina Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina, United States, 27157-1096 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195 United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 收起 <<
NCT00068770	Brain and Central Nervous Syst... 展开 >>em Tumors 收起 <<	Phase 2	Terminated(EORTC trail showed ... 展开 >>TMZ & RT conferred significant survivial in this population) 收起 <<	-	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612-9497 United States, Georgia Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231-2410 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114-2617 United States, North Carolina Comprehensive Cancer Center at Wake Forest University Winston-Salem, North Carolina, United States, 27157-1030 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195 United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 收起 <<
NCT02205931	Epilepsy	Phase 4	Recruiting	June 2019	United Kingdom ... 展开 >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS 0044 1213338149 shakti.agrawal@bch.nhs.uk Principal Investigator: Shakti Agrawal, MBBS Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH Principal Investigator: Andrew Mallick Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA 0044 1223 245151 alasdair.parker@addenbrookes.nhs.uk Principal Investigator: Alasdair Parker, MA Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu Helen.Basu@lthtr.nhs.uk Principal Investigator: Helen Basu Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH 0044 113 243 2799 h.mccullagh@nhs.net Principal Investigator: Helen McCullagh, RCPCH Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS 0044 151 2525163 rachel.kneen@liverpool.ac.uk Principal Investigator: Rachel Kneen, BMBS Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res 0044 207 405 9200 ext 5438 christin.eltze@gosh.nhs.uk Principal Investigator: Christin Eltze, MD Res St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon Penny.Fallon@stgeorges.nhs.uk Principal Investigator: Penny Fallon Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH 0044 161 276 1234 timothy.martland@cmft.nhs.uk Principal Investigator: Tim Martland, RCPCH The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin Anita.Devlin@nuth.nhs.uk Principal Investigator: Anita Devlin Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar Archana.Desurkar@sch.nhs.uk Principal Investigator: Archana Desurkar 收起 <<
NCT02300051	Compulsive Sexual Behavior	Not Applicable	Completed	-	Brazil ... 展开 >> Instituto de Psiquiatria do Hospital das Clínicas da Universidade de São Paulo[University of Sao Paulo General Hospital] São Paulo, Brazil, 05403010 收起 <<
NCT01689389	-		Completed	-	France ... 展开 >> Research Site Argenteuil Cedex, France Research Site Belley, France Research Site Castelmaurou, France Reserach Site Cavaillon, France Research Site Les Mureaux, France Research Site Lille, France Research Site Marseille, France Research Site Montpellier, France Research Site Nimes Cedex, France Research SIte Obernai, France Research Site Paris, France Research Site Rennes, France Research Site Saintes Cedex, France Research Site Sens, France research Site St Dizier, France Research Site St Egreve Cedex, France Research Site Toulouse, France Research Site Tours, France Research Site Ussel Cedex, France 收起 <<
NCT00404248	-		Completed	-	-
NCT00068770	-		Terminated(EORTC trail showed ... 展开 >>TMZ & RT conferred significant survivial in this population) 收起 <<	-	-

拉莫三嗪 /Lamotrigine 99%+

Lamotrigine 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Lamotrigine 质控信息

Lamotrigine 生物活性

Lamotrigine 临床研究

Lamotrigine 参考文献

Lamotrigine 实验方案

Lamotrigine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

5-HT	5-HT (human platelets), IC50:240 μM 5-HT (rat brain synaptosomes), IC50:474 μM
Sodium Channel

拉莫三嗪 /Lamotrigine 99%+

Lamotrigine 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Lamotrigine 质控信息

Lamotrigine 生物活性

Lamotrigine 临床研究

Lamotrigine 参考文献

Lamotrigine 实验方案

Lamotrigine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Lamotrigine 纯度/质量文件产品仅供科研